Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
Sarah K DutcherElnara Fazio-EynullayevaEfe EworukeAmanda CarruthElizabeth C DeeMichael D BlumMichael D NguyenSengwee TohCatherine A PanozzoJennifer G LyonsPublished in: Pharmacoepidemiology and drug safety (2019)
Use of biosimilar filgrastim has increased in the United States, but infliximab biosimilar use remains low. Data on identification of biosimilars in claims data and observed gaps between exposure episodes can be used to support drug safety studies of biosimilars.